IN THE CLAIMS

Please rewrite and add the new claims as follows. Applicant is presenting the claims as amended and is enclosing separate sheets indicating the amendments to the claims with brackets and underlining.

12. (Amended) The tissue-adhesive composition of claim 11, wherein said platelet is derived from said patient.

13. (Amended) The tissue-adhesive composition of claim 11, wherein said composition further comprises plasma.

14. (Amended) The tissue-adhesive composition of claim 13, wherein said plasma is derived from said patient.

A65 15. (Amended) The tissue-adhesive composition of claim 11, wherein said collagen is selected from the group comprising collagen type I, collagen type II, collagen type III, collagen type IV, collagen type V, collagen type IX and collagen type X.

16. (Amended) The tissue-adhesive composition of claim 11, wherein said collagen is acid soluble type I collagen.

17. (Amended) A tissue-adhesive composition formulated for administration to a patient, comprising soluble type I collagen, an extracellular matrix protein, and a platelet derived from said patient.

18. (Amended) The tissue-adhesive composition of claim 17, wherein said composition further comprises plasma derived from said patient.

19. (Amended) A method of treating an intra-articular injury in a subject, the method comprising: contacting the ends of a ruptured tissue from the subject with a composition

comprising soluble type I collagen, a platelet, and at least one of an extracellular protein and a neutralizing agent.

20. (Amended) The method of claim 19, wherein the intra-articular injury is a meniscal tear, ligament tear or a cartilege lesion.

21. (Amended) The method of claim 19, further comprising mechanically joining the ends of the ruptured tissue.

22. (Amended) A method of treating an extra-articular injury in a subject, the method comprising contacting the ends of a ruptured tissue from the subject with a composition comprising soluble type I collagen, a platelet, and at least one of an extracellular protein and a neutralizing agent.

A65 Cancel

23. (Amended) The method of claim 22, wherein the extra-articular injury is a ligament, tendon or muscle injury.

24. (Amended) The method of claim 22, further comprising mechanically joined ends of the ruptured tissue.

25. (New) An implantable prosthesis for repairing a tissue defect in a patient comprising:

a scaffold of biologically implantable material which is amenable to cell migration, cell proliferation, and tissue production between at least two *in vivo* edges of the defect, at least a portion of the scaffold being formed of a composition comprising soluble type I collagen, a platelet, and at least one of an extracellular protein and a neutralizing agent.

R66

26. (New) The prosthesis of claim 25, wherein the composition includes the extracellular protein.

27. (New) The prosthesis of claim 25, wherein the composition includes the neutralizing agent.

28. (New) The prosthesis of claim 25, wherein the tissue defect is a tissue defect in a synovial joint.

29. (New) The prosthesis of claim 28, wherein the tissue defect is a ruptured ligament.

30. (New) The prosthesis of claim 28, wherein the tissue defect is a meniscal tear.

31. (New) The prosthesis of claim 28, wherein the tissue defect is a cartilage lesion.

32. (New) The prosthesis of claim 28, wherein the tissue defect is a ruptured rotator cuff tendon.

33. (New) The prosthesis of claim 25, wherein said composition further comprises plasma.

34. (New) The prosthesis of claim 33, wherein said plasma is derived from the patient.

A 66 Cont

35. (New) The prosthesis of claim 25, wherein said platelet is derived from the patient.

36. (New) The prosthesis of claim 25, wherein said collagen is acid soluble.

37. (New) The prosthesis of claim 25, wherein said collagen is basic soluble.

38. (New) The prosthesis of claim 25, wherein the composition further comprises at least one additive selected from the group comprising insoluble collage, a growth factor, a cross-linking agent, a stem cell, a genetically altered fibroblast, and a cell media supplement.